QQQ   283.85 (+1.18%)
AAPL   142.65 (+1.21%)
MSFT   247.40 (+1.24%)
META   115.33 (+1.23%)
GOOGL   93.71 (-1.30%)
AMZN   90.35 (+2.14%)
TSLA   173.44 (-0.34%)
NVDA   171.69 (+6.51%)
NIO   13.41 (+6.60%)
BABA   94.17 (+6.61%)
AMD   70.47 (+0.47%)
T   19.12 (-0.93%)
MU   55.20 (+2.56%)
CGC   3.09 (-4.63%)
F   13.12 (+0.15%)
GE   83.63 (-1.61%)
DIS   92.55 (+0.43%)
AMC   6.07 (+0.33%)
PYPL   74.22 (-0.27%)
PFE   51.78 (+3.07%)
NFLX   310.26 (+0.60%)
QQQ   283.85 (+1.18%)
AAPL   142.65 (+1.21%)
MSFT   247.40 (+1.24%)
META   115.33 (+1.23%)
GOOGL   93.71 (-1.30%)
AMZN   90.35 (+2.14%)
TSLA   173.44 (-0.34%)
NVDA   171.69 (+6.51%)
NIO   13.41 (+6.60%)
BABA   94.17 (+6.61%)
AMD   70.47 (+0.47%)
T   19.12 (-0.93%)
MU   55.20 (+2.56%)
CGC   3.09 (-4.63%)
F   13.12 (+0.15%)
GE   83.63 (-1.61%)
DIS   92.55 (+0.43%)
AMC   6.07 (+0.33%)
PYPL   74.22 (-0.27%)
PFE   51.78 (+3.07%)
NFLX   310.26 (+0.60%)
QQQ   283.85 (+1.18%)
AAPL   142.65 (+1.21%)
MSFT   247.40 (+1.24%)
META   115.33 (+1.23%)
GOOGL   93.71 (-1.30%)
AMZN   90.35 (+2.14%)
TSLA   173.44 (-0.34%)
NVDA   171.69 (+6.51%)
NIO   13.41 (+6.60%)
BABA   94.17 (+6.61%)
AMD   70.47 (+0.47%)
T   19.12 (-0.93%)
MU   55.20 (+2.56%)
CGC   3.09 (-4.63%)
F   13.12 (+0.15%)
GE   83.63 (-1.61%)
DIS   92.55 (+0.43%)
AMC   6.07 (+0.33%)
PYPL   74.22 (-0.27%)
PFE   51.78 (+3.07%)
NFLX   310.26 (+0.60%)
QQQ   283.85 (+1.18%)
AAPL   142.65 (+1.21%)
MSFT   247.40 (+1.24%)
META   115.33 (+1.23%)
GOOGL   93.71 (-1.30%)
AMZN   90.35 (+2.14%)
TSLA   173.44 (-0.34%)
NVDA   171.69 (+6.51%)
NIO   13.41 (+6.60%)
BABA   94.17 (+6.61%)
AMD   70.47 (+0.47%)
T   19.12 (-0.93%)
MU   55.20 (+2.56%)
CGC   3.09 (-4.63%)
F   13.12 (+0.15%)
GE   83.63 (-1.61%)
DIS   92.55 (+0.43%)
AMC   6.07 (+0.33%)
PYPL   74.22 (-0.27%)
PFE   51.78 (+3.07%)
NFLX   310.26 (+0.60%)
NASDAQ:XERS

Xeris Biopharma - XERS Stock Forecast, Price & News

$1.46
+0.04 (+2.82%)
(As of 12/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.38
$1.46
50-Day Range
$1.22
$1.65
52-Week Range
$1.19
$3.17
Volume
301,126 shs
Average Volume
1.47 million shs
Market Capitalization
$197.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.70

Xeris Biopharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
290.4% Upside
$5.70 Price Target
Short Interest
Bearish
4.68% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.57
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.73) to ($0.50) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.86 out of 5 stars

Medical Sector

755th out of 1,022 stocks

Pharmaceutical Preparations Industry

368th out of 499 stocks

XERS stock logo

About Xeris Biopharma (NASDAQ:XERS) Stock

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company. It engages in developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The firm has three commercial products: Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first and only FDA-approved therapy for primary periodic paralysis, and Recorlev for the treatment of endogenous Cushing's syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Receive XERS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xeris Biopharma and its competitors with MarketBeat's FREE daily newsletter.

XERS Stock News Headlines

SVB Securities Reaffirms Their Buy Rating on Xeris Pharmaceuticals (XERS)
Xeris Biopharma: Q3 Earnings Snapshot
XERS.O - | Stock Price & Latest News | Reuters
Xeris Biopharma: Marching Towards An Inflection Point
See More Headlines
Receive XERS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xeris Biopharma and its competitors with MarketBeat's FREE daily newsletter.

XERS Company Calendar

Last Earnings
11/09/2021
Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/09/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XERS
Fax
N/A
Employees
294
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.70
High Stock Price Forecast
$6.50
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+290.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-122,720,000.00
Net Margins
-134.49%
Pretax Margin
-135.60%

Debt

Sales & Book Value

Annual Sales
$49.59 million
Book Value
$1.43 per share

Miscellaneous

Free Float
128,524,000
Market Cap
$197.88 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Paul R. EdickPaul R. Edick
    Chairman & Chief Executive Officer
  • John Patrick Shannon
    President & Chief Operating Officer
  • Steven M. Pieper
    Chief Financial Officer
  • Steven Prestrelski
    Chief Scientific Officer
  • Ken Johnson
    Senior VP-Clinical Development & Medical Affairs













XERS Stock - Frequently Asked Questions

Should I buy or sell Xeris Biopharma stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Xeris Biopharma in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" XERS shares.
View XERS analyst ratings
or view top-rated stocks.

What is Xeris Biopharma's stock price forecast for 2023?

5 brokerages have issued 12-month price objectives for Xeris Biopharma's shares. Their XERS share price forecasts range from $4.00 to $6.50. On average, they anticipate the company's stock price to reach $5.70 in the next year. This suggests a possible upside of 298.6% from the stock's current price.
View analysts price targets for XERS
or view top-rated stocks among Wall Street analysts.

How have XERS shares performed in 2022?

Xeris Biopharma's stock was trading at $2.93 at the start of the year. Since then, XERS stock has decreased by 51.2% and is now trading at $1.43.
View the best growth stocks for 2022 here
.

When is Xeris Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our XERS earnings forecast
.

How were Xeris Biopharma's earnings last quarter?

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) posted its earnings results on Tuesday, November, 9th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.37) by $0.02. The business earned $11.04 million during the quarter, compared to the consensus estimate of $10.43 million. Xeris Biopharma had a negative net margin of 134.49% and a negative trailing twelve-month return on equity of 161.24%. During the same period in the prior year, the company posted ($0.35) EPS.

What other stocks do shareholders of Xeris Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xeris Biopharma investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Miragen Therapeutics (MGEN), Novan (NOVN), Dynavax Technologies (DVAX), Zosano Pharma (ZSAN), Cogent Biosciences (UMRX) and OrganiGram (OGI).

When did Xeris Biopharma IPO?

(XERS) raised $75 million in an initial public offering on Thursday, June 21st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Mizuho Securities was co-manager.

What is Xeris Biopharma's stock symbol?

Xeris Biopharma trades on the NASDAQ under the ticker symbol "XERS."

Who are Xeris Biopharma's major shareholders?

Xeris Biopharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Stonepine Capital Management LLC (9.54%), BlackRock Inc. (6.07%), Vanguard Group Inc. (4.80%), Armistice Capital LLC (1.85%), State Street Corp (1.60%) and Renaissance Technologies LLC (0.41%). Insiders that own company stock include John Patrick Shannon Jr, Paul R Edick and Steven Prestrelski.
View institutional ownership trends
.

How do I buy shares of Xeris Biopharma?

Shares of XERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xeris Biopharma's stock price today?

One share of XERS stock can currently be purchased for approximately $1.43.

How much money does Xeris Biopharma make?

Xeris Biopharma (NASDAQ:XERS) has a market capitalization of $193.81 million and generates $49.59 million in revenue each year. The company earns $-122,720,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis.

How many employees does Xeris Biopharma have?

The company employs 294 workers across the globe.

How can I contact Xeris Biopharma?

Xeris Biopharma's mailing address is 180 N. LaSalle Street Suite 1810, Chicago IL, 60601. The official website for the company is www.xerispharma.com. The company can be reached via phone at (844) 445-5704 or via email at ir@xerispharma.com.

This page (NASDAQ:XERS) was last updated on 12/8/2022 by MarketBeat.com Staff